Everolimus Tablet shortage
Everolimus Tablet is currently listed in shortage by the FDA. The FDA lists 11 affected products. This page was last refreshed from FDA data on Oct 3, 2026.
Mylan, Endo, and Teva are all permanently stopping production of everolimus tablets. Other makers — Hikma, Novartis, and Upsher-Smith — still list everolimus tablets in 2.5 mg, 5 mg, 7.5 mg, and 10 mg strengths and have not reported a shortage.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Everolimus Tablet. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Mar 2, 2026Currently in shortage11 of 11 products affected.
-
Mar 2, 2026More presentations reported4 more products added to the shortage.
-
Jan 6, 2026FDA refreshed this shortage record4 products updated.
-
Jan 6, 2026More presentations reported4 more products added to the shortage.
-
Nov 3, 2025First reported to the FDA3 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Endo Pharmaceuticals, Inc. 📞 800-828-9393 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Everolimus, Tablet, 5 mg (NDC 49884-125-91) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Everolimus, Tablet, 10 mg (NDC 49884-128-91) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Everolimus, Tablet, 2.5 mg (NDC 49884-119-91) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Everolimus, Tablet, 7.5 mg (NDC 49884-127-91) | — | — | Discontinuation of the manufacture of the drug | — |
Manufacturer: Mylan Pharmaceuticals Inc., a Viatris Company 📞 800-796-9526 3 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Everolimus, Tablet, 2 mg (NDC 0378-0005-85) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Everolimus, Tablet, 3 mg (NDC 0378-0006-85) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Everolimus, Tablet, 5 mg (NDC 0378-0007-85) | — | — | Discontinuation of the manufacture of the drug | — |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Everolimus, Tablet, 10 mg (NDC 0093-7769-24) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Everolimus, Tablet, 5 mg (NDC 0093-7767-24) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Everolimus Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Everolimus Tablet? options further down this page.
Why is Everolimus Tablet in shortage?
Three manufacturers reported here — Mylan Pharmaceuticals (a Viatris Company), Endo Pharmaceuticals, and Teva Pharmaceuticals USA — are all permanently stopping production of their everolimus tablets. Together, the strengths being discontinued across these three companies cover 2 mg, 2.5 mg, 3 mg, 5 mg, 7.5 mg, and 10 mg tablets. None of these manufacturers shared a specific public reason for why they are stopping — the FDA data simply notes "discontinuation of the manufacture of the drug" for each product.
It's worth knowing that this report only reflects these three manufacturers. It does not mean everolimus tablets are going away from every company that makes them — other manufacturers may still be producing this medicine and are listed separately on the FDA's shortage page.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Everolimus Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Everolimus Tablet?
Everolimus tablets are currently on the FDA drug-shortage list. I want to walk you through what this means so you can plan your next steps calmly.
Three manufacturers who filed this report — Mylan, Endo, and Teva — have all listed their everolimus tablets as a discontinuation. This affects every strength on their records: 2 mg, 2.5 mg, 3 mg, 5 mg, 7.5 mg, and 10 mg. None of these three companies is reporting an available source right now. Because the reason given is discontinuation rather than a temporary delay, this particular supply problem may be lasting, which makes a conversation with your prescriber the right next step.
Importantly, this report covers only those three makers. Other companies still list everolimus on the market — Hikma, Novartis (Afinitor and Afinitor Disperz), and Upsher-Smith (Torpenz) — all offering the same medicine, though they may not be in your local pharmacy's stock today.
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers for your strength.
- Your pharmacy may be able to source the same medicine from another maker listed above, if available.
- Ask your prescriber or pharmacist about options, such as a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Everolimus Tablet?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Everolimus Tablet is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Everolimus | EVEROLIMUS 2.5 mg/1 | Tablet · Oral | Hikma Pharmaceuticals USA Inc. | 00054-0480-13 |
| Everolimus | EVEROLIMUS 5 mg/1 | Tablet · Oral | Hikma Pharmaceuticals USA Inc. | 00054-0481-13 |
| Everolimus | EVEROLIMUS 10 mg/1 | Tablet · Oral | Hikma Pharmaceuticals USA Inc. | 00054-0482-13 |
| Everolimus | EVEROLIMUS 7.5 mg/1 | Tablet · Oral | Hikma Pharmaceuticals USA Inc. | 00054-0497-13 |
| Afinitor | EVEROLIMUS 5 mg/1 | Tablet · Oral | Novartis Pharmaceuticals Corporation | 00078-0566-51 |
| Afinitor | EVEROLIMUS 10 mg/1 | Tablet · Oral | Novartis Pharmaceuticals Corporation | 00078-0567-51 |
| Afinitor | EVEROLIMUS 2.5 mg/1 | Tablet · Oral | Novartis Pharmaceuticals Corporation | 00078-0594-51 |
| Afinitor | EVEROLIMUS 7.5 mg/1 | Tablet · Oral | Novartis Pharmaceuticals Corporation | 00078-0620-51 |
| Afinitor Disperz | EVEROLIMUS 2 mg/1 | Tablet, For Suspension · Oral | Novartis Pharmaceuticals Corporation | 00078-0626-51 |
| Afinitor Disperz | EVEROLIMUS 3 mg/1 | Tablet, For Suspension · Oral | Novartis Pharmaceuticals Corporation | 00078-0627-51 |
| Afinitor Disperz | EVEROLIMUS 5 mg/1 | Tablet, For Suspension · Oral | Novartis Pharmaceuticals Corporation | 00078-0628-51 |
| Torpenz | EVEROLIMUS 2.5 mg/1 | Tablet · Oral | Upsher-Smith Laboratories, LLC | 00245-0822-04 |
Therapeutic equivalents & pricing 30 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Everolimus 5 mg | Hikma | 30 tablets | $14.771 | AB | Availability likely |
| Everolimus 5 mg | Teva | 28 tablets | $14.771 | AB | Discontinued |
| Torpenz 5 mg | Upsher-Smith | 28 tablets | $14.771 | AB | Availability likely |
| Everolimus 5 mg | Par | 28 tablets | $14.771 | — | Discontinued |
| Everolimus 5 mg | Breckenridge | 28 tablets | $14.771 | AB | Availability likely |
| Everolimus 5 mg | Biocon | 28 tablets | $14.771 | AB | Availability likely |
| Everolimus 5 mg | NorthStar | 30 tablets | $14.771 | AB | Availability likely |
| Yulithira 5 mg | CivicaScript, | 30 tablets | $14.771 | AB | Availability likely |
| Everolimus 10 mg | Hikma | 30 tablets | $26.324 | AB | Availability likely |
| Everolimus 10 mg | Teva | 28 tablets | $26.324 | AB | Discontinued |
| Torpenz 10 mg | Upsher-Smith | 28 tablets | $26.324 | AB | Availability likely |
| Everolimus 10 mg | Breckenridge | 28 tablets | $26.324 | AB | Availability likely |
| Everolimus 10 mg | Biocon | 28 tablets | $26.324 | AB | Availability likely |
| Everolimus 10 mg | NorthStar | 30 tablets | $26.324 | AB | Availability likely |
| Yulithira 10 mg | CivicaScript, | 30 tablets | $26.324 | AB | Availability likely |
| Everolimus 10 mg | Par | 28 tablets | $26.324 | — | Discontinued |
| Afinitor 5 mg | Novartis | 28 tablets | — | AB | FDA listed |
| Everolimus 5 mg | Natco | 28 tablets | — | AB | FDA listed |
| everolimus 5 mg | Novugen | 28 tablets | — | AB | FDA listed |
| Everolimus 5 mg | Amneal | 7 tablets | — | AB | FDA listed |
| Everolimus 5 mg | Breckenridge | 7 tablets | — | AB | FDA listed |
| Afinitor Disperz 5 mg | Novartis | 1 tablet | — | AB | FDA listed |
| Everolimus 5 mg | Biocon | 28 tablets | — | AB | FDA listed |
| Afinitor 10 mg | Novartis | 28 tablets | — | AB | FDA listed |
| Everolimus 10 mg | Natco | 28 tablets | — | AB | FDA listed |
| everolimus 10 mg | Novugen | 28 tablets | — | AB | FDA listed |
| Everolimus 2.5 mg | Hikma | 30 tablets | — | AB | FDA listed |
| Afinitor 2.5 mg | Novartis | 28 tablets | — | AB | FDA listed |
| Everolimus 2.5 mg | Teva | 28 tablets | — | AB | Discontinued |
| Torpenz 2.5 mg | Upsher-Smith | 28 tablets | — | AB | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Everolimus Tablet — that fall in the same broad treatment class (antineoplastic - mtor kinase inhibitors) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Everolimus Tablet shortage FAQs
Is Everolimus Tablet in shortage?
Which products are affected?
When will Everolimus Tablet be available again?
Can I still get Everolimus somewhere?
What should I do if I take Everolimus Tablet?
Still have a question about the Everolimus Tablet shortage?
Ask a pharmacist about this shortage →View Everolimus Tablet on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.